As a mid-career pediatric rheumatologist and the sole one at my center in Louisiana, leading a Phase 1 CAR-T trial for lupus has been an extraordinary learning experience. I share my reflections and perspective in the hope that it may be helpful to colleagues venturing into this increasingly familiar territory.
Recent News
Read ArticleACR Convergence 2026 closed on a high note with the Clinical Year in Preview, a forward-looking session on the final day presented by Alexis Ogdie, MD, MSCE, of the University of Pennsylvania.
article
Dr. John Cush
Tweet
Who might benefit from GLP-1s in your rheumatology clinic? Join Drs. Catherine Bakewell and Leonard Calabrese at https://t.co/9THCAABeZ0, Jan 30–31 in Dallas, TX, or live online. Kick off 2027 with 12.5 CME credits. Early bird pricing through Dec 15.
https://t.co/xjuAWKqAY9 https://t.co/xhqg94lmoy
Dr. John Cush
Tweet
FDA has approved secukinumab (Cosentyx) 150 mg for treatment of polymyalgia rheumatica pts who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper https://t.co/5JQmHwvjoi https://t.co/cR6UvOkcEa
Dr. John Cush
Tweet
Pioneers & Progress in Pediatric Rheumatology: The 50th Anniversary
Dr. Susan Shenoi | "Mastering the Field of Pediatric Rheumatology: Pioneers and Progress, 50th Anniversary" |ACR 2026
https://t.co/hSx8LHR99s https://t.co/cQNLQkT6qp
Dr. John Cush
Tweet
📢 "We can't have a one-size-fits-all approach" – Dr. Saakshi Khattri
Hear Dr. Khattri and Lindsay Tom, PA-C, explore the latest IL-23i and JAKi data and how it impacts their PsA treatment decisions. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/MOBlwXCFuu https://t.co/PtGCWWwBjY
Dr. John Cush
Tweet
Dr. John Cush
Tweet
FDA has approved secukinumab (Cosentyx) 150 mg for the treatment of adult patients with polymyalgia PMR w/ an inadequate response to steroids or who cannot tolerate steroid taper.https://t.co/WrlLYrLRds
Dr. John Cush
Tweet
FDA has approved secukinumab (Cosentyx) 150 mg for the treatment of adult patients with polymyalgia PMR w/ an inadequate response to steroids or who cannot tolerate steroid taper.https://t.co/xkdUobmNTA
Dr. John Cush
Tweet
FDA has approved secukinumab (Cosentyx) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.https://t.co/vaUYXwglVB
Dr. John Cush
Tweet
Not All Pain in Rheumatic Disease is Inflammatory
In a session at the Global Rheumatology Summit, Dr. Daniel Clauw, an expert on the topic, explained that fibromyalgia can occur in isolation in a “top-down” fashion, or can be secondary to inflammatory autoimmune diseases in a https://t.co/AMUm52SKsB
Dr. John Cush
Tweet
Missed #ACR26? Or just trying to catch up?
Dr. Jack Cush shares why he returns to ACR Convergence every year—and how to make the most of this year's research with RheumNow recaps, expert analysis, podcasts & RheumIQ.
Catch up: https://t.co/1bELsAsOXw https://t.co/ZQRt4GUUPM
Dr. John Cush
Tweet
Points to Consider in D2M/Treatment Refractory axSpA
New ASAS guidance presented at #ACR26 outlines 10 points to consider, from diagnostic reassessment to inflammation, mimics & treatment adherence.
Dr. Sheila Reyes breaks it down: https://t.co/vvT2qWbbM7 https://t.co/Crf5uisIvS
Dr. John Cush
Tweet
To Pulse or Not to Pulse in ANCA Associated Vasculitis?
New #ACR26 data found no significant remission benefit with pulse steroids, but serious infections were higher (31% vs 14%). Is it time to rethink their use?
Dr. Michael Putman weighs in: https://t.co/b6cJkI2aXc https://t.co/rM3eoRBJYW
David Liew
Tweet
What does CAR-T safety look like between autoimmune disease and heme-onc?
Here's CRS and ICANS within the cohorts so far
(although don't forget about the lymphodepletion)
Anca Askanase @HSpecialSurgery #ACR26 @RheumNow https://t.co/GkDGDiOET4
Dr. John Cush
Tweet
Two Prescriptions, One Patient
Obesity, in particular in PsA was widely covered at #ACR26. In the Swiss SCQM registry, 63.6% of 2,087 patients with PsA were overweight or obese, compared with 31% overweight and 12% obese in the Swiss population, and higher BMI tracked disease https://t.co/Ys5wTvQ2r9
Dr. John Cush
Tweet
ACR 2026 Day 4 Report
The last day of ACR 2026 was a half-day but a busy day, with several exciting reports, especially coming from the late-breaking abstracts.
https://t.co/wBfrQhwZHy https://t.co/plZgG0Y7VN
Dr. John Cush
Tweet
ACR 2026: RA Topic Panel https://t.co/4Jttct8XKe
Dr. John Cush
Tweet
TRBV9+ a novel treatment approach for AxSpA?
https://t.co/sNV9KsgvNa https://t.co/b6fRnwdLYf
Dr. John Cush
Tweet
Check the genetics in your patients with ILD
A common misconception is that genetic variants don’t cause disease in adults, says Dr. Korf. According to Dr. Bogunovic, 1 in 4 adults will have a first manifestation of genetic error of immunity in adulthood. Genetics seems to be https://t.co/qRUV0oiu0a

Poster Hall